Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 8
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT03747159 SynBioSe-2 — Synergetic B-cell Immunomodulation in SLE - 2nd Study. |
Belimumab Injection | Lupus | Phase 3 | COMPLETED | En attente / non publié | Leiden University Medical Center | Netherlands · HagaZiekenhuis, The Hague, Netherlands … | 2018-10-01 → 2026-06-22 | Ouvrir |
| NCT06411249 A Study Describing the Efficacy and Safety of Belimumab Administered in… |
Belimumab (GSK1550188) | Lupus | Phase 4 | ACTIVE_NOT_RECRUITING | En attente / non publié | GlaxoSmithKline | United States, Argentina, Brazil, France, Germany, Gr… | 2024-06-06 → 2029-07-17 | Ouvrir |
| NCT04767698 Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multip… |
Belimumab | SEP | Phase 2 | TERMINATED | En attente / non publié | Johns Hopkins University | United States · Johns Hopkins University, Baltimore, … | 2021-10-01 → 2022-05-10 | Ouvrir |
| NCT07720310 Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupu… |
CAR T cells chimeric antigen rece… | Lupus | À vérifier | ENROLLING_BY_INVITATION | En attente / non publié | N.N. Alexandrov National Cancer C… | Belarus · NN Alexandrov National Cancer Centre of Bel… | 2026-03-09 → 2030-06 | Ouvrir |
| NCT07611214 PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifr… |
LUPKYNIS | Lupus | Phase 4 | RECRUITING | En attente / non publié | Aurinia Pharmaceuticals Inc. | United States · Accurate Clinical Research, Inc., Lak… | 2026-04-22 → 2029-03-02 | Ouvrir |
| NCT01516450 Japanese phase1 Study of Belimumab (IV vs SC) |
GSK1550188 IV | Lupus | Phase 1 | COMPLETED | En attente / non publié | GlaxoSmithKline | Japan · GSK Investigational Site, Tokyo, Japan | 2011-12-26 → 2012-04-11 | Ouvrir |
| NCT05917288 A Study of Belimumab in Chinese Pediatric Participants With Systemic Lu… |
Belimumab | Lupus | Phase 1 | COMPLETED | En attente / non publié | Johns Hopkins University | China · GSK Investigational Site, Beijing, China | GS… | 2023-07-07 → 2024-10-30 | Ouvrir |
| NCT03125486 Compassionate Use for Subcutaneous (SC) Belimumab |
SC belimumab 200 mg | Lupus | À vérifier | NO_LONGER_AVAILABLE | En attente / non publié | GlaxoSmithKline | United States · GSK Investigational Site, Milwaukee, … | Non communiqué | Ouvrir |